Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KISS1R | Q969F8 | 15/20 | 0.66 |
| ▸ | IL1RN | P18510 | 1/20 | 0.63 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.63 |
| ▸ | NPY4R | P50391 | 4/20 | 0.63 |
| ▸ | NPY1R | P25929 | 3/20 | 0.63 |
| ▸ | NPY2R | P49146 | 2/20 | 0.63 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29615834 | 0.95 | KISS1R (0.73) | KISS1R | |
| SCHEMBL30449287 | 0.95 | KISS1R (0.73) | KISS1R | |
| SCHEMBL30786659 | 0.94 | KISS1R (0.69) | KISS1R | |
| SCHEMBL30786656 | 0.93 | KISS1R (0.64) | KISS1RIL1RNERAP2NPY4RNPY1R | |
| SCHEMBL30757406 | 0.92 | IL1RN (0.63) | KISS1RIL1RNERAP2NPY4RNPY1R | |
| SCHEMBL29416090 | 0.92 | KISS1R (0.65) | KISS1R | |
| SCHEMBL30567424 | 0.91 | NPY4R (0.60) | KISS1RIL1RNERAP2NPY4RNPY1R | |
| SCHEMBL23314250 | 0.91 | KISS1R (0.68) | KISS1RNPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL30272517 | 0.91 | KISS1R (0.66) | KISS1R | |
| SCHEMBL31257039 | 0.91 | IL1RN (0.65) | KISS1RIL1RNERAP2NPY4RNPY1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4735055-A1 | UROKINASE-TYPE PLASMINOGEN ACTIVATOR RECEPTOR (UPAR)-PET/CT IN BRAIN TUMOURS | Curasight A/S (DK) | 2026-05-06 | — | — | EP | disclosed |
| US-20250319215-A1 | UROKINASE-TYPE PLASMINOGEN ACTIVATOR RECEPTOR (UPAR)-PET/CT IN HEAD AND NECK SQUAMOUS CELL CARCINOMAS (HNSCCS) | CURASIGHT AS (DK) | 2025-10-16 | — | — | US | disclosed |
| US-20250049971-A1 | UROKINASE-TYPE PLASMINOGEN ACTIVATOR RECEPTOR (UPAR)-PET/CT IN NEUROENDOCRINE NEOPLAMS | CURASIGHT A/S (DK) | 2025-02-13 | — | — | US | disclosed |
| WO-2025003190-A1 | UROKINASE-TYPE PLASMINOGEN ACTIVATOR RECEPTOR (UPAR)-PET/CT IN BRAIN TUMOURS | CURASIGHT A/S (DK) | 2025-01-02 | — | — | WO | disclosed |
| CN-118846138-A | Compositions comprising fluorophore-labeled uPAR targeting peptide conjugates | 荧光向导股份公司 | 2024-10-29 | — | — | CN | disclosed |
| CN-115379864-A | Compositions comprising fluorophore-labeled uPAR-targeting peptide conjugates | 荧光向导股份公司 | 2022-11-22 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250049971-A1 | UROKINASE-TYPE PLASMINOGEN ACTIVATOR RECEPTOR (UPAR)-PET/CT IN NEUROENDOCRINE NEOPLAMS | PLAUR, PLAU, PROKR1 | KISS1R 252/4885IL1RN 94/4885ERAP2 290/4885 |
| US-20250319215-A1 | UROKINASE-TYPE PLASMINOGEN ACTIVATOR RECEPTOR (UPAR)-PET/CT IN HEAD AND NECK SQUAMOUS CELL CARCINOMAS (HNSCCS) | PLAUR, PLAU, SERPINE1 | KISS1R 665/4885IL1RN 143/4885ERAP2 286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.